Aytu Bioscience (NASDAQ:AYTU) Upgraded by ValuEngine to “Buy”

ValuEngine upgraded shares of Aytu Bioscience (NASDAQ:AYTU) from a hold rating to a buy rating in a report issued on Thursday morning, ValuEngine reports.

Several other equities research analysts also recently commented on the stock. Zacks Investment Research upgraded shares of Aytu Bioscience from a hold rating to a strong-buy rating and set a $2.25 target price on the stock in a research note on Friday, May 17th. Northland Securities restated a buy rating and issued a $10.00 target price on shares of Aytu Bioscience in a research note on Tuesday.

AYTU traded down $0.12 during trading on Thursday, reaching $1.39. 197,573 shares of the company’s stock were exchanged, compared to its average volume of 335,468. Aytu Bioscience has a fifty-two week low of $0.68 and a fifty-two week high of $6.96. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.10 and a quick ratio of 3.76. The firm has a 50 day moving average of $1.77. The company has a market cap of $25.99 million, a P/E ratio of -0.05 and a beta of 4.74.

Aytu Bioscience (NASDAQ:AYTU) last issued its earnings results on Tuesday, May 14th. The company reported ($0.50) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.11. Aytu Bioscience had a negative net margin of 184.35% and a negative return on equity of 81.04%. The company had revenue of $2.38 million for the quarter, compared to the consensus estimate of $2.00 million. Sell-side analysts anticipate that Aytu Bioscience will post -2.2 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the company. Searle & CO. boosted its stake in shares of Aytu Bioscience by 1,241.6% in the 2nd quarter. Searle & CO. now owns 201,247 shares of the company’s stock valued at $380,000 after purchasing an additional 186,247 shares in the last quarter. Geode Capital Management LLC bought a new position in shares of Aytu Bioscience in the fourth quarter valued at about $43,000. Finally, Virtu Financial LLC bought a new position in shares of Aytu Bioscience in the first quarter valued at about $30,000. Institutional investors own 15.13% of the company’s stock.

About Aytu Bioscience

Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.

Further Reading: Why is the price-sales ratio important?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.